An infectious disease expert discusses using motivational interviewing and empathetic communication to address vaccine ...

The recombinant zoster vaccine protects adults with HIV against cardiovascular complications such as incident heart failure ...

META Older Latino adults show high motivation for RSV vaccination but face significant barriers to actual immunization.

FDA approves Hibsago (bepirovirsen) with NrtI therapy for adult chronic hepatitis B without cirrhosis; phase 3 trials show up to 20% functional cure at 72 weeks.

Treatment-experienced patients with HIV and viremia achieve high virologic suppression with long-acting CAB/RPV.

At IDWeek 2026, Paul Sax, MD, and Cynthia Sears, MD, highlighted practice-changing developments bridging clinical infectious ...

Switching to a once-daily bictegravir/lenacapavir (BIC/LEN) single-tablet regimen is generally well tolerated through 48 ...

The Infectious Disease Advisor team will be covering emerging research and key takeaways from IDWeek 2026, as well as ...

Patient COVID-19 status does not significantly alter the microbiology of device-associated hospital-acquired infections or ...

Two respiratory syncytial virus (RSV) vaccines, RSVPreF3+AS01 and RSVpreF, were highly effective at preventing hospital admissions and death among older adults during the 2023 to 2024 season. These ...

The FDA has approved Hovilpri for immunocompromised adults with refractory mucocutaneous HSV lesions, offering a novel oral treatment.

During the 2024-2025 season, influenza vaccination effectively lowered the risk for hospitalization and severe inpatient outcomes among adults.